These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6133660)

  • 1. Effect of labetalol and YM-09538 on neuronal uptake of (3H)norepinephrine in the rat vas deferens.
    Cohen ML; Hynes LM
    Clin Exp Hypertens A; 1983; 5(4):563-75. PubMed ID: 6133660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of labetalol on the uptake of [3H]-(-)-noradrenaline into the isolated vas deferens of the rat.
    Drew GM; Hilditch A; Levy GP
    Br J Pharmacol; 1978 Jul; 63(3):471-4. PubMed ID: 667491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats.
    Honda K; Takenaka T; Shiono K; Miyata-Osawa A; Nakagawa C
    Jpn J Pharmacol; 1985 May; 38(1):31-41. PubMed ID: 2862302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of combined alpha-beta-blockade. I.
    Louis WJ; McNeil JJ; Drummer OH
    Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
    Monopoli A; Bamonte F; Forlani A; Ongini E; Parravicini L
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):256-63. PubMed ID: 6151824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Labetalol blockade of central alpha- and beta-noradrenergic receptors in rat brain homogenates.
    Devoto P; Stefanini E; Marchisio AM; Vernaleone F; Collu R
    Pharmacol Res Commun; 1980 Feb; 12(2):177-82. PubMed ID: 6104337
    [No Abstract]   [Full Text] [Related]  

  • 7. Affinities for alpha- and beta-adrenoceptor subtypes of YM-09538, a new combined alpha- and beta-adrenoceptor antagonist, by radioligand binding assay.
    Asano M; Hashimoto H; Nakashima M
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):34-46. PubMed ID: 6135396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical evidence for the dual action of labetalol on alpha- and beta-adrenoceptors.
    Aggerbeck M; Guellaen G; Hanoune J
    Br J Pharmacol; 1978 Apr; 62(4):543-8. PubMed ID: 26446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxy derivative (YM-11133).
    Honda K; Takenaka T; Miyata-Osawa A; Terai M
    J Pharmacol Exp Ther; 1986 Mar; 236(3):776-83. PubMed ID: 2869143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypotensive and vascular effects of labetalol in the normotensive rat and dog.
    Hashimoto K; Hashimoto T; Iizuka H; Tsukada T; Matsuda H; Imai S
    Jpn Heart J; 1978 Sep; 19(5):762-74. PubMed ID: 32409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the correlation between alpha-adrenoceptor blockade and inhibition of neuronal uptake of 3H-noradrenaline.
    Kapur H; Mottram DR
    Pharmacol Res Commun; 1979 Jan; 11(1):45-53. PubMed ID: 34177
    [No Abstract]   [Full Text] [Related]  

  • 12. Adrenoceptor blocking effects of arotinolol, a new combined alpha- and beta-adrenoceptor blocking agent.
    Miyagishi A; Nakahara H; Hara Y
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):249-62. PubMed ID: 6210068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interaction of labetalol with alpha- and beta-adrenergic receptors : biochemical study (author's transl)].
    Dausse JP; Guicheney P; Maich PJ; Meyer P
    Nouv Presse Med; 1978 Oct; 7(35):3121-3. PubMed ID: 31601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of alpha 1-adrenoceptors and functional consequences in the bisected rat vas deferens following chronic inhibition of neuronal noradrenaline uptake.
    Sallés J; Badia A
    Br J Pharmacol; 1993 Mar; 108(3):678-83. PubMed ID: 8096783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacology of labetalol, an alpha- and beta-adrenoceptor blocking agent.
    Blakeley AG; Summers RJ
    Gen Pharmacol; 1978; 9(6):399-402. PubMed ID: 32121
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.
    Sybertz EJ; Sabin CS; Pula KK; Vliet GV; Glennon J; Gold EH; Baum T
    J Pharmacol Exp Ther; 1981 Aug; 218(2):435-43. PubMed ID: 6114171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alpha-adrenoceptor agents on norepinephrine release from vas deferens of several species including man.
    Belis JA; Colby JE; Westfall DP
    Eur J Pharmacol; 1982 Mar; 78(4):487-90. PubMed ID: 6122590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.